A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Inflammatory Bowel Diseases
• Crohn's Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 85 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites